Benefits of Attending:
- Gain an understanding of recent evidence that allows you to optimize clinical decision-making for your patients with ALL
- Hear from the experts on how they approach ALL cases you typically encounter in your clinical practice
- Learn cutting-edge testing strategies, including evolving roles for MRD, in monitoring and treatment planning among patients with ALL
- Compare your practices with those of the experts in caring for your adolescent and young adults, as well as other adult populations, with ALL
Agenda Topics
- Optimizing the Use of Monoclonal Antibodies and Bispecific Agents in ALL
- Improving Outcomes for Patients With Philadelphia Chromosome–Positive ALL
- Uncovering the Role of Measurable/Minimal Residual Disease in the Clinical Management of ALL
- What's New With CAR T-Cell Therapy in ALL?
- New Biologic Insights and New Therapies for Patients With ALL
Program Chair:
Elias Jabbour, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Faculty:
Nicola Gökbuget, MD
Head of Study Center
Department of Medicine II, Hematology/Oncology
Goethe University Hospital
Frankfurt, Germany
Stephan Grupp, MD, PhD
Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Chief, Cellular Therapy and Transplant Section
Director, Cancer Immunotherapy Frontier Program
Children's Hospital of Philadelphia
Oncology/BMT
Philadelphia, PA
Dieter Hoelzer, MD, PhD
Emeritus Director of Internal Medicine
University of Frankfurt
Frankfurt, Germany
Hagop M. Kantarjian, MD
Professor and Chair, Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Benefits of Attending:
- Hear the latest information on novel treatments for HLH
- Learn how the experts apply the latest data
- Interact with our expert panel to discuss HLH management
Agenda Topics
- Making the Appropriate Diagnosis of Hemophagocytic Lymphohistiocytosis (HLH) in 2019 and 2020
- Treating HLH and Managing the Patient: Best Practices From the Experts
- Illustrated Case Reviews and Moderated Panel Discussion
- Recent Clinical Trials of Interest and ASH 2019 Preview
Program Chair:
Michelle L. Hermiston, MD, PhD
Associate Professor
Department of Pediatrics
UCSF School of Medicine
Pediatric Hematologist and Oncologist
Benioff Children's Hospital
University of California, San Francisco
San Francisco, CA
Faculty:
Ashish R Kumar, MD, PhD
Professor of Pediatrics
Division of Bone Marrow Transplantation and Immune Deficiency
Director, Langerhans Cell Histiocytosis Center
Director, Hematology/Oncology Fellowship Program
Cincinnati Children's Hospital Medical Center
Bone Marrow Transplantation and Immune Deficiency
University of Cincinnati College of Medicine
Cincinnati, OH
Kenneth L. McClain, MD, PhD
Professor, Pediatrics-Oncology
Baylor College of Medicine
Director, Histiocytosis Program
Director, Pediatric Lymphoma-Histiocytosis Fellowship Program
Texas Children's Hospital
Houston, TX
Philip A. Roehrs, MD
Director, Pediatric Blood and Marrow Transplants
Levine Children’s Cancer & Blood Disorders
Carolinas Medical Center
Charlotte, NC
Benefits of Attending:
- Discover agents that are in late stages of clinical development for relapsed/refractory DLBCL
- Collaborate with lead clinical trial investigators that determine the efficacy and safety of novel agents for relapsed/refractory DLBCL
- Prepare to incorporate novel therapeutics into current treatment strategies for your most difficult cases, including patients that are ineligible for stem cell transplant
Agenda Topics
- Current Strategies to Assess Risk in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- What Is the Outcome With Current First-Line Standards of Care?
- Unmet Needs in Patients With Relapsed/Refractory DLBCL
- Recent Data With New Approaches in Relapsed/Refractory DLBCL: Focus on Transplant-Ineligible Patients
- Next Steps to Address Unmet Needs of Transplant-Ineligible Patients With Relapsed/Refractory DLBCL
Program Chair:
Gilles A. Salles, MD, PhD
Professor of Medicine and Hematology
Claude Bernard University of Lyon
Head of the Department of Hematology
Lyon-Sud University Hospital Complex
Pierre-Bnite, France
Faculty:
Ranjana Advani, MD
Saul A Rosenberg Professor of Lymphoma
Stanford Cancer Institute
Stanford, CA
Marie José Kersten, MD, PhD
Professor of Hematology
Head, Department of Hematology
Amsterdam University Medical Centers
University of Amsterdam
Amsterdam, Netherlands
Kami J. Maddocks, MD
Associate Professor of Clinical Internal Medicine
Lymphoma Program Director
Division of Hematology, Department of Internal Medicine
The James Cancer Hospital at The Ohio State University
Columbus, OH
Ana Younes, MD
Professor and Chief, Lymphoma service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Benefits of Attending:
- Evaluate risk scoring algorithms and the evolving role of molecular profiling in myeloproliferative neoplasms (MPNs), including primary myelofibrosis and polycythemia vera
- Integrate trial findings into clinical cases to better manage your patients with MPNs
- Analyze ongoing clinical trials across MPNs and assess the potential for enrolling specific groups of patients in these studies
Agenda Topics
- An overview of MPNs: histological and molecular characteristics and their impact on clinical decisions
- JAK-STAT signal transduction in MPNs: how do JAK inhibitors fit in the evolving treatment paradigm?
- Understanding the evolving treatment landscape in MPNs
- Multidisciplinary Tumor Board Discussion
Program Chair:
Ronald Hoffman, MD
Albert A. and Vera G. List Professor of Medicine
Director, Myeloproliferative Disorders Research Program
Tisch Cancer Institute
Mount Sinai School of Medicine
New York, NY
Faculty:
Rami S. Komrokji, MD
Senior Member
Section Head - Leukemia & MDS
Vice Chair - Department of Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, FL
Ann Mullally, MD
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Abdulraheem Yacoub, MD
Associate Professor of Medicine
Clinical Director of Ambulatory Hematology Clinics
University of Kansas Medical Center
Kansas City, KS
Benefits of Attending:
- Explore biomarkers for GvHD
- Discover novel strategies for GvHD prophylaxis
- Examine emerging therapies for GvHD
Agenda Topics
- Overview of Graft-Versus-Host Disease (GvHD) and Unmet Needs
- Emerging Prophylaxis Strategies to Prevent the Incidence of GvHD
- Acute GvHD Therapy and Recent Advances
- Exploring Novel Biomarkers to Identify Acute GvHD and Chronic GvHDin Your Practice
- Emerging Therapeutic Opportunities for Chronic GvHD
Program Chair:
Corey S. Cutler, MD, MPH, FRCPC
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, MA
Faculty:
Shernan Holtan, MD
Associate Professor of Medicine
Division of Hematology, Oncology, and Transplantation
University of Minnesota
Minneapolis, MN
James L. M. Ferrara, MD, DSc
Ward-Coleman Chair in Cancer Medicine
Professor of Medicine and Pediatrics
Director, Hematologic Malignancies Translational Research Center
Icahn School of Medicine at Mount Sinai
New York, NY
Madan Jagasia, MBBS, MS, MMHC
Professor of Medicine, Division of Hematology-Oncology
Chief Medical Officer, Vanderbilt-Ingram Cancer Center
Co-Leader, Translational Research and Interventional Oncology Research Program
Vanderbilt University Medical Center
Nashville, TN
Iskra Pusic, MD
Assistant Professor
Department of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia
Washington University School of Medicine
St. Louis, MO
